5 weeks. Enhanced connectivity with the regional species pool and increased aggregation of habitat patches also affected multiple response variables, especially those associated with microbes, and in some cases reduced the effects of drought to a small extent. This indicates that spatial processes might play a role in the resilience of communities and ecosystem functioning, given enough time. These effects were however insufficient to facilitate significant recovery in algal growth before seasonal die-back began in autumn. The limited resilience of ecosystem functioning in our experiment suggests that even short-term droughts can have extended consequences for stream ecosystems in the world's vast boreal region, and especially on the ecosystem processes and services mediated by algal biofilms. This article is protected by copyright. All rights reserved.BACKGROUND AND AIMS In about 20% of children with cholestasis and normal or low serum gamma-glutamyltransferase (GGT) activity, no etiology is identified. We sought new genes implicated in pediatric hepatobiliary disease. METHODS We conducted whole exome sequencing in 69 children evaluated at our center from 2011 to 2018 who had low-GGT cholestasis and in whom homozygous / compound heterozygous predictedly pathogenic variants (PPV) in ATP8B1, ABCB11, NR1H4, MYO5B, or TJP2 were not found. Clinical records and findings on light microscopy and transmission electron microscopy of liver-biopsy materials were reviewed. RESULTS In 7 patients from 7 unrelated families, biallelic PPV (10 in total) were found in USP53, recently associated with intrahepatic cholestasis. Seven variants were classified as pathogenic one canonical splicing, c.569+2T&gt;C, and six nonsense or frameshifting c.169C&gt;T (p.Arg57Ter), c.581delA (p.Arg195GlufsTer38), c.831_832insAG (p.Val279GlufsTer16), c.1012C&gt;T (p.Arg338Ter), c.1426C&gt;T (p.Arg476Ter), and c.1558C&gt;T (p.Arg520Ter). Three were likely pathogenic c.297G&gt;T (p.Arg99Ser), c.395A&gt;G (p.His132Arg), and c.878G&gt;T (p.Gly293Val). In all patients, jaundice began at age less then 7mo. Cholestasis was transient, with documented resolution of hyperbilirubinemia in all (oldest patient now aged 5y) except one, who was lost to follow-up. Light microscopy identified intralobular cholestasis, giant-cell change of hepatocytes, and perisinusoidal-perihepatocytic and portal-tract fibrosis. Ultrastructural study revealed elongated hepatocyte-hepatocyte tight junctions. One patient was deaf. CONCLUSION USP53 interacts with the tight-junction constituent TJP2. https://www.selleckchem.com/products/azd7648.html TJP2 mutation can cause low-GGT intrahepatic cholestasis, with elongated hepatocyte-hepatocyte tight junctions, as well as deafness. Our findings extend a preliminary report of USP53 disease and indicate that USP53 mutation may generate a partial phenocopy of TJP2 disease. (250 words). This article is protected by copyright. All rights reserved.OBJECTIVE Compare the long-term effects of tocolysis with nifedipine or atosiban on child outcome at age 2.5-5.5 years. DESIGN The APOSTEL III trial was a multicentre RCT that compared tocolysis with nifedipine or atosiban in 503 women with threatened preterm birth. ?Neonatal outcomes did not differ between both treatment arms, except for a higher incidence of intubation in the atosiban group. METHODS Parents were asked to complete four questionnaires regarding neurodevelopment, executive function, behaviour problems, and general health. MAIN OUTCOME MEASURES Main long-term outcome measure was a composite of abnormal development at the age of 2.5-5.5 years. RESULTS Of the 426 women eligible for follow up, 196 (46%) parents returned the questionnaires of 115 children in the nifedipine and 110 children in the atosiban group. Abnormal development occurred in 32 children (30%) in the nifedipine group and 38 children (38%) in the atosiban group (OR 0.74, 95% CI 0.41-1.34). The separate outcomes for neurodevelopment, executive function, behaviour, and general health showed no significant differences between the groups. Sensitivity analysis including all children of the APOSTEL III trial including a comparison of deceased children resulted in a higher rate of healthy survival in the nifedipine group (64% versus 54%), but no significant difference in overall mortality (5.4% versus 2.7%). There were no significant subgroup effects. CONCLUSION Outcomes on broad child neurodevelopment, executive function, behaviour and general health were comparable in both groups. Neither nifedipine nor atosiban can be considered as the preferred treatment for women with threatened preterm birth. This article is protected by copyright. All rights reserved.OBJECTIVES We aimed to determine the impact of washout period in patients with multiple myeloma between bortezomib-based induction regimens and the collection of stem cells. METHODS This was a single center historical prospective study, including all sequential newly diagnosed patients with myeloma between 2012 and 2017 that were given a first line bortezomib-based induction therapy (?6 cycles) followed by stem cell collection (n=75). RESULTS We found a statistically significant correlation between the days from last dose of bortezomib and both CD34+cells/kg yield on the first collection day and the overall collected CD34+cells/kg (r=0.466, p less then 0.001 and r=0.341, p=0.03, respectively). The optimal receiver operating curve's cutoff point was 8.5 days (sensitivity-79% and specificity-71%, p=0.001). On multivariate analysis timing of last dose of bortezomib remained statistically significant (p=0.01). Based on this, we developed a model to predict the total collected CD34+ cells/kg = 11.76+ 0.13 (timing in days of last dose of bortezomib) - 0.1 (age) - 1.39 (if female) -0.01 (?PR) -1.35 (if prior radiation). CONCLUSIONS Timing of last dose of bortezomib may predict a successful collection. A washout period of 9 days is associated with a better collection yield. A prospective validation of this novel finding is required. This article is protected by copyright. All rights reserved.Curcumin, a dietary polyphenol and major constituent of Curcuma longa (Zingiberaceae), is extensively used as a spice&nbsp;in Asian countries. For&nbsp;ages, turmeric has been used in traditional medicine systems to treat various diseases, which was&nbsp;possible because of its&nbsp;anti-inflammatory, antioxidant, anticancerous, antiepileptic, antidepressant, immunomodulatory, neuroprotective, antiapoptotic, and antiproliferative effects. Curcumin has potent antioxidant, anti-inflammatory, antiapoptotic, neurotrophic activities, which support its&nbsp;plausible neuroprotective effects in neurodegenerative disease. However, there is limited information available regarding the clinical efficacy of curcumin in neurodegenerative cases. The low oral bioavailability of curcumin may be speculated as a plausible factor&nbsp;that limits its effects in humans. Therefore, utilization of several approaches for the enhancement of bioavailability may improve clinical outcomes. Furthermore, the use of nanotechnology and a targeted drug delivery system may improve the bioavailability of curcumin.